Health Care [ 10/12 ] | Biotechnology [ 64/73 ]
NASDAQ | Common Stock
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease.
Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy.
It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance.
The company is based in Calgary, Canada.
Reported date | EPSChange YoY | EstimateSurprise |
---|---|---|
May 14, 25 | 0.04 Decreased by -97.04% | - |
Mar 31, 25 | -0.81 Decreased by -26.70% | -0.41 Decreased by -94.17% |
Nov 12, 24 | -0.20 Increased by +69.82% | - |
Aug 14, 24 | 0.06 Increased by +107.33% | -0.92 Increased by +106.35% |
May 15, 24 | 1.35 Increased by +1.33 K% | -0.28 Increased by +588.04% |
Dec 31, 23 | -0.64 Decreased by -218.00% | -0.81 Increased by +21.96% |
Nov 14, 23 | -0.67 Decreased by -292.27% | -0.19 Decreased by -252.63% |
Aug 14, 23 | -0.80 Decreased by -566.67% | -1.36 Increased by +41.18% |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Mar 31, 25 | 0.00 Decreased by N/A% | -698.67 K Increased by +76.86% | Decreased by N/A% Decreased by N/A% |
Dec 31, 24 | 0.00 Decreased by N/A% | 119.08 K Decreased by -95.59% | Increased by +N/A% Decreased by N/A% |
Sep 30, 24 | 0.00 Decreased by N/A% | -587.01 K Increased by +55.98% | Decreased by N/A% Decreased by N/A% |
Jun 30, 24 | 0.00 Decreased by N/A% | 170.07 K Increased by +110.05% | Increased by +N/A% Decreased by N/A% |
Mar 31, 24 | 0.00 Decreased by N/A% | -3.02 M Decreased by -64.79% | Decreased by N/A% Decreased by N/A% |
Dec 31, 23 | 0.00 Decreased by N/A% | 2.70 M Increased by +192.50% | Increased by +N/A% Decreased by N/A% |
Sep 30, 23 | 0.00 Decreased by N/A% | -1.33 M Increased by +14.66% | Decreased by N/A% Decreased by N/A% |
Jun 30, 23 | 0.00 Decreased by N/A% | -1.69 M Decreased by -6.99% | Decreased by N/A% Decreased by N/A% |